Edgewise Therapeutics (EWTX) drew fresh investor attention after reporting favorable Phase 2 Part D CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy, with results supporting progression to Phase 3 development.

The Phase 2 CIRRUS-HCM update lands at a time when Edgewise Therapeutics has already seen strong momentum, with a 1-month share price return of 12.57% and a year-to-date share price return of 54.99%. The 1-year total shareholder return of 159.59% and very large 3-year total shareholder return suggest recent gains are building on an already powerful rerating.

If the EDG-7500 readout has you looking at other potential growth stories in healthcare, this is a good moment to see what else is moving with 38 healthcare AI stocks.

After such strong recent gains and with Edgewise Therapeutics trading about 31% below the average analyst price target of US$48.17, the key question is whether there is still a buying opportunity here or if markets are already reflecting expectations for future growth.

Preferred Price-to-Book Multiple of 8x: Is It Justified?

With EDG-7500 progressing and Edgewise Therapeutics shares at $36.81, investors are also weighing what the current valuation is implying about future outcomes.

The key yardstick available here is the price-to-book ratio, which compares the company’s market value to its accounting book value. For Edgewise Therapeutics, that figure sits at 8x, while peers average 4.8x and the broader US pharmaceuticals group averages 2.2x. That places the stock at a clear premium to both its direct peer set and the wider industry.

Given that Edgewise Therapeutics currently reports no revenue and a loss of $176.01m, a higher P/B ratio suggests the market is putting a lot of value on the company’s clinical pipeline and the potential for future revenue growth that is forecast at 36.9% per year. The question for you is whether that premium aligns with your view on the probability and timing of future approvals and commercialization.

Against the US pharmaceuticals industry average P/B of 2.2x, the 8x multiple stands out as materially higher. This points to expectations that are well above what the market is assigning to many established drug developers. Without a fair value P/B “target” to compare against, there is limited guidance on where that multiple could settle if sentiment shifts, so the current premium is doing most of the talking.

Result: Price-to-book of 8x (OVERVALUED)

However, Edgewise Therapeutics still carries clear risks, including its lack of current revenue and reliance on successful clinical outcomes to justify a US$3.96b valuation.

Next Steps

Feeling torn between the optimism around Edgewise Therapeutics and the clear risks still on the table? Take a closer look at both sides of the story through 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Edgewise Therapeutics?

Do not stop with Edgewise Therapeutics; use this momentum to widen your watchlist and give yourself more high quality options for your next move.

• Target resilience by scanning companies with sturdier finances and lower perceived risk using the 66 resilient stocks with low risk scores.
• Hunt for quality at a reasonable price by reviewing companies flagged as 45 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies in the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.